ZA200809114B - Antisecretory protein for use in the treatment of compartment syndrome - Google Patents

Antisecretory protein for use in the treatment of compartment syndrome

Info

Publication number
ZA200809114B
ZA200809114B ZA200809114A ZA200809114A ZA200809114B ZA 200809114 B ZA200809114 B ZA 200809114B ZA 200809114 A ZA200809114 A ZA 200809114A ZA 200809114 A ZA200809114 A ZA 200809114A ZA 200809114 B ZA200809114 B ZA 200809114B
Authority
ZA
South Africa
Prior art keywords
treatment
compartment syndrome
tumour
antisecretory
antisecretory protein
Prior art date
Application number
ZA200809114A
Other languages
English (en)
Inventor
Hansson Hans-Arne
Lange Stefan
Bergstroem Tomas
Jennische Eva
Original Assignee
Lantmaannen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmaannen As Faktor Ab filed Critical Lantmaannen As Faktor Ab
Publication of ZA200809114B publication Critical patent/ZA200809114B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • AIDS & HIV (AREA)
ZA200809114A 2006-04-27 2008-10-23 Antisecretory protein for use in the treatment of compartment syndrome ZA200809114B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0600933 2006-04-27

Publications (1)

Publication Number Publication Date
ZA200809114B true ZA200809114B (en) 2009-06-24

Family

ID=38655929

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200809114A ZA200809114B (en) 2006-04-27 2008-10-23 Antisecretory protein for use in the treatment of compartment syndrome
ZA200809116A ZA200809116B (en) 2006-04-27 2008-10-23 Further medical uses of antisecretory protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200809116A ZA200809116B (en) 2006-04-27 2008-10-23 Further medical uses of antisecretory protein

Country Status (19)

Country Link
US (2) US8309513B2 (enExample)
EP (2) EP2363140B1 (enExample)
JP (2) JP5323682B2 (enExample)
KR (3) KR20090045148A (enExample)
CN (3) CN101460187B (enExample)
AT (1) ATE526031T1 (enExample)
AU (1) AU2007244003B2 (enExample)
BR (2) BRPI0710794A2 (enExample)
CA (1) CA2650589C (enExample)
DK (3) DK2037950T3 (enExample)
ES (3) ES2374712T3 (enExample)
IL (1) IL194774A (enExample)
MX (1) MX2008013774A (enExample)
NZ (2) NZ572257A (enExample)
PL (2) PL2040734T3 (enExample)
RU (2) RU2465914C2 (enExample)
SG (1) SG171601A1 (enExample)
WO (1) WO2007126363A2 (enExample)
ZA (2) ZA200809114B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007244005B2 (en) * 2006-04-27 2012-08-02 Lantmannen As-Faktor Ab Further medical uses of antisecretory protein
SG171602A1 (en) 2006-04-27 2011-06-29 Lantmaennen As Faktor Ab Use of antisecretory factors for treating intraocular hypertension
CN101460187B (zh) 2006-04-27 2014-11-05 兰特门内阿斯-法克托尔公司 抗分泌蛋白的进一步医疗应用
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
US8901083B2 (en) 2008-11-25 2014-12-02 Temple University Administration of angiocidin for the treatment of leukemia
EP2396024A4 (en) * 2009-02-11 2013-02-27 Lantmaennen As Faktor Ab USE OF ANTISECRREATORY FACTORS (AF) FOR OPTIMIZATION OF CELLULAR ABSORPTION
JP6707121B2 (ja) 2015-07-10 2020-06-10 ラントメネン・アーエス−ファクトール・アーベー 高含量のaf−16を有する卵黄の産生方法
MX2019000594A (es) 2016-07-18 2019-09-09 Lantmaennen As Faktor Ab Factor anti-secretor 17.
JP7217760B2 (ja) * 2018-06-28 2023-02-03 ラントメネン・メディカル・アーベー 急性呼吸不全の治療および/または予防の使用のための抗分泌因子
EP3855935A1 (en) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB A consumable product comprising malted wheat
EP3855934A2 (en) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB A consumable product comprising malted dehulled oat
CN115605214A (zh) 2020-03-26 2023-01-13 兰特门内保健食品公司(Se) 用于促进身体活动恢复的包含麦芽化谷物的可消耗产品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) * 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE506486C2 (sv) * 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
US7662169B2 (en) * 2000-09-05 2010-02-16 Wittmann Dietmar H Prosthesis and method for lowering abdominal pressure
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
AU2007244005B2 (en) 2006-04-27 2012-08-02 Lantmannen As-Faktor Ab Further medical uses of antisecretory protein
CN101460187B (zh) 2006-04-27 2014-11-05 兰特门内阿斯-法克托尔公司 抗分泌蛋白的进一步医疗应用
WO2009052478A1 (en) * 2007-10-19 2009-04-23 Trustees Of Boston University Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide

Also Published As

Publication number Publication date
CN104689299B (zh) 2020-02-21
CN101460187B (zh) 2014-11-05
JP5285043B2 (ja) 2013-09-11
RU2008146731A (ru) 2010-06-10
AU2007244003A1 (en) 2007-11-08
KR20090045148A (ko) 2009-05-07
RU2008146734A (ru) 2010-06-10
NZ572257A (en) 2011-10-28
IL194774A (en) 2015-07-30
WO2007126363A2 (en) 2007-11-08
KR20140141729A (ko) 2014-12-10
ES2472737T3 (es) 2014-07-02
ES2615515T3 (es) 2017-06-07
JP2011032284A (ja) 2011-02-17
AU2007244003B2 (en) 2012-08-02
IL194774A0 (en) 2011-08-01
WO2007126363A8 (en) 2008-10-30
KR101757523B1 (ko) 2017-07-12
WO2007126363A3 (en) 2008-03-13
EP2040734A2 (en) 2009-04-01
BRPI0710794A2 (pt) 2011-06-21
JP5323682B2 (ja) 2013-10-23
KR20140123601A (ko) 2014-10-22
CA2650589A1 (en) 2007-11-08
EP2040734B1 (en) 2011-09-28
SG171601A1 (en) 2011-06-29
MX2008013774A (es) 2009-02-03
HK1131738A1 (en) 2010-02-05
PL2363140T3 (pl) 2017-05-31
US8309513B2 (en) 2012-11-13
DK2363140T3 (en) 2017-03-06
US8389468B2 (en) 2013-03-05
EP2363140B1 (en) 2016-12-14
DK2037950T3 (da) 2014-06-30
JP2009535328A (ja) 2009-10-01
CN101460187A (zh) 2009-06-17
CA2650589C (en) 2017-06-13
KR101805973B1 (ko) 2017-12-06
US20090185982A1 (en) 2009-07-23
EP2363140A1 (en) 2011-09-07
NZ572256A (en) 2012-02-24
CN104689299A (zh) 2015-06-10
US20110305773A1 (en) 2011-12-15
RU2457853C2 (ru) 2012-08-10
RU2465914C2 (ru) 2012-11-10
DK2040734T3 (da) 2012-01-23
CN101437533A (zh) 2009-05-20
PL2040734T3 (pl) 2012-04-30
ES2374712T3 (es) 2012-02-21
CN101437533B (zh) 2016-10-12
ATE526031T1 (de) 2011-10-15
ZA200809116B (en) 2009-07-29
BRPI0710858A2 (pt) 2011-05-17

Similar Documents

Publication Publication Date Title
ZA200809114B (en) Antisecretory protein for use in the treatment of compartment syndrome
BR112019021822A2 (pt) Terapia de combinação
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
EA201290356A1 (ru) Композиции для лечения тошноты и рвоты центрального происхождения
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
DK2305255T3 (da) Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
ATE511889T1 (de) Partikeltherapieanlage
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
EP2571573A4 (en) PHOTOTHERAPY BY CAPSULE
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
MX390506B (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
CY1117394T1 (el) Λιξισενατιδη για χρηση στην θεραπευτικη αντιμετωπιση της στενωσης ή/και αποφραξης στο συστημα παγκρεατικων πορων
BR112013007423A2 (pt) terapia combinada no que diz respeito ao tratamento da infecção por hcv
BR112022012283A2 (pt) Combinações
WO2011056566A3 (en) Compounds and methods for treatment of cancer
NZ599499A (en) Use of a neuregulin to treat peripheral nerve injury
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
EA200900735A1 (ru) Применение слитого антигена mage a3-белок d в имунотерапии в сочетании с хирургическим вмешательством, химиотерапией или радиотерапией для лечения рака
WO2008144659A3 (en) Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers
BR112022012284A2 (pt) Combinações
DK1720540T3 (da) Satraplatin til behandling af resistente tumorer eller tumorer, der er vanskelige at behandle
WO2007031853A3 (en) Therapeutic combination of hamlet and a hdac inhibitor to treat cancer